Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2022 Sep 29;17(9):e0267221. doi: 10.1371/journal.pone.0267221

Phenotypic and genotypic detection of extended spectrum beta lactamase enzyme in Klebsiella pneumoniae

Aso Bakr Mohammed 1, Khanda Abdullateef Anwar 2,*
Editor: Monica Cartelle Gestal3
PMCID: PMC9522270  PMID: 36173938

Abstract

Background

Klebsiella species are ubiquitous in nature and can be found in the natural environment and on mucosal surfaces of mammals and it is an important multidrug-resistant pathogen affecting humans and is a major source for hospital acquired infections. The aim of this study is to investigate the prevalence of ESBL enzyme among Klebsiella pneumoniae isolates by phenotypic methods from different hospital wards and detection of ESBL resistance genes such as TEM and SHV in Sulaimani city/ Kurdistan–Iraq.

Methods

Klebsiella pneumoniae isolates were collected from different clinical samples from different hospitals, the isolates were identified by standard technique. Screening of ESBLs was undertaken by using double disk diffusion and standard disk diffusion methods. Real-time PCR was used for genotypic detection of TEM and SHV genes according to the standard protocol.

Result

Out of 54 Klebsiella pneumoniae isolates; 28 were ESBL positive, The pattern of antimicrobial susceptibility testing showed that the most resistant antibiotic are AMP (100%), AMC (100%) followed by CAZ (83.33%), CTX (75.9%), CPM (74%), ATM (70.37%). Both TEM and SHV genes were detected among 28 (51.85%) ESBL positive by using Real-time PCR method.

Conclusion

SHV gene was detected in most of the isolates of ESBL producers of Klebsiella pneumoniae.

Introduction

Extended-spectrum beta-lactamase (ESBL) one of the most common types of antibiotic resistance found in Enterobacteriaceae, plasmid-mediated enzymes capable of hydrolyzing a β-lactam bond in commonly prescribed β-lactam antibiotics, such as penicillins, broad spectrum cephalosporins and aztreonam [1] these enzymes have been clustered into nine different structural and evolutionary families based on their amino acid sequence.

TEM and sulphydryl variable SHV were the major types however, CTX-M type is more common in some countries [2] and they are rapidly evolving and produced by Gram negative bacteria, and have the ability to hydrolyse all cephalosporins, aztreonam, and related oxyimino-beta lactams as well as older penicillins but this can be inhibited by clavulanic acid [3].

The plasmids that harbor ESBL genes also carry genes for other antibiotic classes such as aminoglycosides, chloramphenicol, sulfonamides, trimethoprim, and tetracycline. Thus, Gram negative bacilli containing these plasmids mostly are MDR bacteria [4].

A large number of outbreaks of infections due to ESBL producing organisms have been described all over the world. In some hospitals, initial outbreaks of infections have been supplanted by endemicity of the ESBL producing strains [5]. This may lead to increased patient mortality, therefore, control of the initial outbreak of ESBL producing organisms in a hospital or specialized unit of a hospital is of critical importance [6].

About 400 different types of ESBLs have been recognized around the world, among which TEM and SHV were more prevalent, mutations occurring in the genes encoding TEM and SHV enzymes lead to the development of ESBLs that have an expanded substrate profile [7].

Both TEM and SHV types are derived from penicillinase that is characterized by several single amino-acid substitutions, these mutations allow them to hydrolyze extended spectrum cephalosporins [8].

TEM-1 is the most commonly encountered β-lactamase in Gram-negative bacteria. Up to 90% of ampicillin resistance in E. coli is due to the production of this enzyme, and it is also responsible for the ampicillin and penicillin resistance that is seen in H. influenzae and N. gonorrhoeae [9].

The fact that, patients most likely to become infected with ESBL-producing Enterobacteriaceae are those with prolonged stays in the intensive care unit (ICU). Failure to rapidly detect ESBL-producing strains may result in serious consequences, such as treatment failure and death [10].

It is estimated that Klebsiella pneumoniae cause 8% of all hospital-acquired infections. In the USA it comprise 3% to 7% of all nosocomial bacterial infections, this place them among the eight most common pathogens in hospitals and second only to E. coli as the most common cause of Gram-negative sepsis [11], while urinary tract is the most common site for infection of Klebsiella species and it accounts for 6 to 17% of all nosocomial urinary tract infections (UTI) and shows an even higher incidence in specific groups of patients at risk, such as patients with neuropathic bladders or with diabetes mellitus [12].

The likelihood of Klebsiella pneumoniae hospital-acquired infections is greatly increased by the presence of invasive devices, such as catheters, and ventilator associated pneumoniae in hospitalized patients [13].

Antimicrobial resistance in Klebsiella pneumoniae has been attributed largely to the acquisition of large, self-conjugating plasmids. These are extra chromosomal DNA molecules that encode factors promoting the initiation of replication, independently from the replication of the bacterial chromosome, maintain a constant copy number per bacterial cell and regulate their own replication rate [14].

Carriage of multiple β-lactamase genes in the same strain is a known ability of Klebsiella pneumoniae and may contribute to the selective success of this pathogen [15]. Combinations of all types of bla genes were reported in this species, this may be due to either carriage of an antibiotic-resistant plasmid encoding an array of antibiotic resistance genes or due to acquisition of transposons containing different bla genes on the same plasmid [10].

Many different techniques exist for confirming ESBL production, Phenotypic tests for ESBL detection only confirm whether an ESBL is produced but cannot detect the ESBL subtype. Some ESBLs may fail to reach a level to be detected by disk diffusion tests but result in treatment failure in the infected patient [16], while those utilizing similar methodology to standardized susceptibility tests are the most convenient for the routine diagnostic laboratory. These all depend on detecting synergy between clavulanic acid and the indicator cephalosporin used in the primary screening [17].

Another confirming method involves at least an eight-fold reduction in the MICs of ceftazidime or cefotaxime in the presence of clavulanic acid, the isolates then reported as resistant to all penicillins, cephalosporins and aztreonam [8].

Early detection of β-lactamase genes was performed using DNA probes those were specific for TEM and SHV genes. However, using DNA probes can sometimes be rather labor intensive. The easiest and most common molecular method used to detect the presence of a β-lactamase belonging to a family of enzymes is PCR with oligonucleotide primers that is specific for a β-lactamase gene [18].

Molecular methods appears to be sensitive in spite to that its expensive, time consuming and require specialized equipment and expertise [19].

Determination of TEM and SHV genes by molecular techniques in ESBL producing bacteria and their pattern of antimicrobial resistance can supply useful data about their epidemiology and risk factors associated with these infections [20].

Methods

This cross sectional study was carried out in different hospitals (Shar teaching hospital, and Dr. Jamal Ahmed Rashid hospital) in Sulaimani city from a period of March to July 2019. Ethical approval was obtained from Directorate of Health of Sulaimani.

Fifty-four isolates of Klebsiella pneumoniae were collected from all the mentioned hospitals from different infection sites and the samples underwent processing through standard bacteriological technique by doing Gram stain and culture technique for all the isolates [21].

All isolated Klebsiella pneumoniae were tested by string test through formation of a viscous filament ≥5 mm after stretching a bacterial single colony (Fig 1) with a standard bacteriological loop on an agar plate [22, 23] VITEK 2 bioMerieux GN76 / ID card machine was used for the identification of all isolated Klebsiella according to the manufacturer’s recommendations. Bacterial strains which were identified biochemically were preserved for longer period by transferring a fresh colony from newly culture plates to prepare 0.5 mL bacterial suspension in tryptic soya broth and they incubated for 18 hours at 37°C in shaking incubator, after which 0.5 mL of this growth cultures was mixed with 0.5 mL of sterile 80% glycerol solution in a Eppendorf tube. After labeling the tubes with numbers and dates of preservation and stored in a deep freezer at -70°C [24].

Fig 1. String test: A hypermucoviscous phenotype is seen when a viscous filament ≥ 5 mm is produced after stretching of Klebsiella pneumoniae colony with a loop on agar plate.

Fig 1

Antibiotic susceptibility pattern of Klebsiella pneumoniae isolates were performed according to the Kirby–Bauer discs diffusion method [25] by using 15 commonly used antibiotic agents; Ampicillin (AMP), Amoxicillin-Clavulanic Acid (AMC), Piperacillin-tazobactam (PTZ), Cefoxitin (FOX), Ceftazidime (CAZ), Ceftriaxone (CRO), Cefotaxime (CTX), Cefepime (CFM), Aztronam (ATM), Imipenem (IPM), Meropenem (MEM), Amikacin (AN), Gentamicin (CN), Ciprofloxacin (CIP), Trimethoprim- Sulphomethoxazole (TMP), and all of the inoculated plates were aerobically incubated at 37°C for 18–24 hours, and the results were interpreted based on the instruction provided by the CLSI [26].

Detection of extended spectrum β-lactamase enzyme

All isolates of Klebsiella pneumoniae were screened for ESBL enzyme production by using various antimicrobial disks, ESBL positive meant the bacteria shows high level (co-resistance) to third generation cephalosporin and monobactams such as: Ceftazidime zone ≤ 22 mm, Aztreonam zone ≤ 27 mm, Cefotaxime zone or Ceftriaxone zone ≤ 25 mm [26].

Double disk synergy test (DDST)

The double-disk synergy method is integrated as an adjunct of the routine susceptibility test. In this test, a disk of amoxicillin-clavulanic acid AMC (30μg) and disks of the third generation Cephalosporin antibiotic such as Ceftazidime CAZ disk (30μg), Cefotaxime CTX (30μg), Ceftriaxone CRO (30μg), and Cefepime FEP (10μg), were used together with Aztronam ATM (30μg), each disks were placed at a distance of 20 mm apart from the inhibitor disk on a lawn culture of the resistant isolate on Mueller-Hinton Agar plate. The presence of ESBL was inferred when the inhibition zone around any of the antibiotic disks was enhanced on the side of the Clavulanic acid-containing disk (Fig 2), resulting in a characteristically shaped zone referred to as a “keyhole [27].

Fig 2. Double disc synergy test for ESBL.

Fig 2

Detection of ESBL by VITEK 2 compact system

Each isolate was tested using the VITEK 2 system with the antimicrobial susceptibility test extend AST-EXN8 card. This system was designed to perform both screening and confirmatory tests for phenotypic detection of ESBL on the same plate [28].

Genotypic detection of ESBL enzyme

Two genes (blaSHV and blaTEM) were selected in this study to be analyzed by real time PCR. Bacterial reactivation was performed by thawing frozen samples (bacterial culture and glycerol), and sub cultured on blood agar then incubated for 24 hours, selected colony from blood agar was sub cultured in to Tryptic soy broth for 18 hours incubated at 37°C, and samples were ready for plasmid extraction [29].

Primer preparation

Two sets of primers were used in this study and the primers were designed by Macrogen/Korea both forward and revers primer were designed previously “Table 1” [30].

Table 1. bla SHV and bla TEM primer sequence.
Target gene Nucleotide Amplicon size (bp) Reference
bla TEM gene -F 5-TCCGCTATGAGACAATAACC-3 296 Doosti et al., 2015
bla TEM gene -R 3-ATAATACCGCACCACATAGCAG-5
bla SHV gene -F 5-TACCATGAGCGATAACAGCG-3 450
bla SHV gene -R 3-GATTTGCTGATTTCGCTCGG-5

Primers were prepared according to what was recommended by manufacturer (Macrogen) by dissolving lyophilized primer in 300 μL of DNA and RNA injection water to final concentration of stock primers at 100 pmol/μL. and dilution of 1:10 (10 μL of stock primer with 90 μL of DNA and RNA free distil water) were accepted to prepare a final working primer in concentration 10 pmol/μL [31].

Plasmid extraction was performed as recommended by the manufacturer of (MagCore®, RBC bioscience) automated nucleic acid extraction kit (Taiwan), prior to plasmid extraction, the content of the kit was prepared and checked as recommended.

SYBR green real-time PCR for blaTEM and blaSHV detection

Real-time PCR was used to detect of TEM and SHV genes, PCR was performed by rapid cycling in a reaction volume 20 μL including (master mix, amplification primers, extracted nucleic acid, and DNA and RNA free distil water). All isolates with ESBL positive by phenotypic methods were underwent plasmid extraction by automated nucleic acid extractor, 7.5 μL of extracted nucleic acid in concentration 10 ng/μL mixed with 10 μL of qPCR master mix and 1.5 of DNA and RNA deionized water, 0.5μl of forward primer and 0.5 μl of reverse primer at concentration 10 ng/μl then added in to the reaction mic PCR tube and the condition of PCR, after that the reaction tube subjected the thermo cycling reaction on bio molecular system (BMS) model instrument (Australia), according PCR condition used in amplification cycle “Table 2”.

Table 2. Programs of real-time PCR thermocycling condition after serial optimization.
Gene Initial dentauration °C/time Denaturation Annealing Extension Number of cycle Final extention
bla HSV 95°C/5 minute 94/ °C 40 sec 59/ °C 40 sec 72/ °C 40 sec 35 72/ °C 40 sec
Bla TEM 95°C/5 minute 94/ °C 40 sec 59/ °C 40 sec 72/ °C 40 sec 30 72/ °C 40 sec

A negative control was included in each run to access specificity of primers and possible contamination. The threshold cycle (Ct) was determined as the PCR cycle at which increased reporter fluorescence above the baseline could be detected.

All samples were run on PCR machine, PCR reaction data were plotted on graphic presentation by Micro software PCR program.

Statistical analysis. All data were analyzed by transfer to excel sheet data, by using Microsoft Excel 2010 and P value < 0.05 was regarded as significant.

Results

Fifty four suspected colonies of Klebsiella pneumonia were collected from different hospital laboratories in Sulaimani city, out of 54 samples; 29 (53.7%) of all specimen were males and 25 (46.3%) female, with male to female ratio 1.15:1.

All colonies of 54 samples showed pink color, moist and mucoid colony on the surface of MacConkey agar and large grey color colony on blood agar with no hemolytic property among all isolated bacteria. Out of the 54 isolated Klebsiella pneumonia, only 8 samples were positive to hypermucoviscosity phenomena according to what was described previously [32].

Out of 54 specimens which had been received; the highest numbers were taken from intensive care unit 32, (59.26%), followed by dialysis center 5 (9.26%), 3 (5.55%) for each of Pediatric and outpatient, and other wards in hospitals 11 (20.37%) that is illustrated in “Table 3”. The result indicate that among all specimens taken from all hospital wards; urine were 23 (42.6%), followed by Endotracheal aspiration 12 (22.22%), blood 11 (20.37%), catheter tip 4 (7.41), wound swab 3 (5.55%), and 1 (1.85%) was recorded for sputum.

Table 3. Clinical specimens and source of samples of Klebsiella pneumoniae.

Specimen ICU Dialysis Pediatric OPD Others Total
Urine 9 1 2 3 8 23(42.6%)
Blood 8 1 1 0 1 11(20.37%)
ETA 11 0 0 0 1 12(22.22%)
Cathetre tip 1 3 0 0 0 4(7.41%)
Sputum 1 0 0 0 0 1(1.85%)
Wound swab 2 0 0 0 1 3(5.55%)
Total 32(59.26%) 5 (9.26%) 3(5.55%) 3(5.55%) 10(20.37%) 54(100%)

ICU: Intensive care unit, OPD: Outpatient clinic, ETA: Endotracheal aspiration.

Table 2” All confirmed samples were tested for antimicrobial susceptibility testing, by using Kirby-Bauer disc diffusion method and the result were analyzed according to CLSI [21]. The susceptibility results against 15 antimicrobial agents is shown in the “Table 4”and it was found that the most resistant drug were ampicillin followed by amoxiclave and cetftazidim.

Table 4. Antimicrobial susceptibility testing for Klebsiella pneumoniae.

Antibiotics Resistant Intermediate Sensitive
AMP 54(100%) 00(0%) 00(0%)
AMC 54(100%) 00(0%) 00(0%)
PTZ 35(64.8%) 3(5.55%) 16(29.6%)
FOX 26(48.1%) 1(1.85%) 27(50%)
CAZ 45(83.33%) 00(0%) 9(16.66%)
CTX 41(75.9%) 00(0%) 13(24.1%)
CPM 40(70.4%) 00(0%) 14(25.9%)
ATM 38(70.37%) 00(0%) 16(29.63%)
IMP 20(37.0%) 00(0%) 34(62.96%)
MEM 20(37.0%) 00(0%) 34(62.96%)
AN 26(48.1%) 00(0%) 28(51.9%)
CM 30(55.5%) 11(1.85%) 23(42.6%)
CIP 34(62.96%) 2(3.7%) 18(33.33%)
TEM 30(55.5%) 0(0%) 24(44.44%)

Ampicillin (AMP), Amoxicillin-Clavulanic Acid (AMC), Piperacillin-tazobactam (PTZ), Cefoxitin (FOX), Ceftazidime (CAZ), Ceftriaxone (CRO), Cefotaxime (CTX), Cefepime (CFM), Aztronam (ATM), Imipenem (IPM), Meropenem (MEM), Amikacin (AN), Gentamicin (CN), Ciprofloxacin (CIP), Trimethoprim- Sulphomethoxazole (TMP).

In this study 54 isolates of Klebsiella pneumoniae were screened for ESBL production by using standard disk diffusion method [21]. The result showed that 40 (74.0%) isolates were resistance for 3rd generation of cephalosporins (ESBL producer), while 14 (26.0%) was susceptible for 3rd generation of cephalosporin (non ESBL producer).

All confirmed Klebsiella pneumoniae were tested for ESBL by double disk synergy method. The selected bacterial samples were tested against 3rd generation cephalosporin and characteristic key hole appearance were observed in 28 (51.85%) samples. At the same time all samples were tested by VITEK 2 compact system for ESBL and the same results were obtained. The rate of both methods was illustrated in Table 5 and statistically this relation is significant (P value < 0.05).

Table 5. Percentage of ESBL by screen and confirmation test.

ESBL test ESBL screen positive ESBL screen negative Total
ESBL confirmation positive 28 0 28
ESBL confirmation negative 12 14 26
Total 40 14 54

Proportion of multidrug-resistance among isolates of Klebsiella pneumoniae

Multidrug resistance pattern were analyzed among all isolated Klebsiella pneumonia (Bora et al. 2014), any strain that shows resistant to at least one antibiotic in each group of three or more classes of antimicrobials reported as multidrug-resistance MDR [29]. Out of 54 samples of isolated Klebsiella pneumoniae; 32 (59.29%) were MDR “Table 6”, and among all MDR; 75% were ESBL positive “Table 7”.

Table 6. Percentage of MDR among Klebsiella pneumoniae.

Resistant profile Klebsiella pneumoniae number = 54
Resistant to one group 11 (20.37%)
Resistant to two groups 11 (20.37%)
Resistant to three groups 15 (27.77%)
Resistant to four groups 17 (31.48%)
MDR (multi drug resistant) 32 (59.25%)

Table 7. Relation of MDR and ESBL.

ESBL/MDR MDR Non-MDR Toatal
ESBL positive 21(75%) 7(25%) 28(100%)
ESBL negative 11(42.3%) 15(57.7%) 26(100%)
Total 32(59.26%) 22(40.74%) 54(100%)

Molecular detection of ESBL

Both ESBL genes (bla EM and bla SHV) were selected to be tested in this study by using real-time PCR. The result demonstrated that 26 isolates (92.85%) were positive for blaSHV gene (Figs 3 and 4) and 15 isolates (53.57%) were positive for blaTEM gene (Fig 5), and 15 isolates (53.57%) have both blaSHV and blaTEM genes, and 2 isolates (3.70%) out of ESBL positive isolates found to be negative to both genes.

Fig 3. SYBR green real-time PCR amplification result of blaSHV gene after 35 cycle (fluorescence versus cycle number).

Fig 3

Fig 4. Melting curve (fluorescence versus temperature) of blaSHV gene amplification products.

Fig 4

Fig 5. SYBR green real-time PCR amplification result of blaTEM gene after 30 cycle (fluorescence versus cycle number).

Fig 5

Discussion

Klebsiella pneumoniae is one of the most important multidrug resistant pathogenic bacteria that cause several diseases such as, burns infections, urinary and respiratory tract infections, wounds and blood infections and liver abscess.

All isolated Klebsiella pneumoniae in this study were from different wards in hospitals where different samples were analyzed and received from different clinical condition. 42.6% from all samples were urine specimen, this result is in agreement with study done in Erbil-Iraq; whom reporting higher percentage of urine sample 71.7%, this indicate that urinary tract infection is the most common infection in hospitals and Klebsiella is the second most common isolated bacteria after E. coli in this condition [31, 33]. The likelihood of Klebsiella pneumoniae hospital-acquired infections is greatly increased by the presence of invasive devices, such as catheters and ventilator associated pneumoniae in hospitalized patients and risk of infection increase with those patients with neuropathy bladder and diabetes mellitus [13].

The second most common specimen was blood (20.37%), which accounts for more than 70% and most of were of intensive care unit that indicates presence of more critical patients in this unite and they need blood culture continuously to exclude sepsis by gram negative bacteria. Klebsiella pneumoniae can persist on environmental surfaces human skin, within the respiratory, urinary tracts and easily transferred among patients via clinical operations and examinations, and it has become one of the most frequent outbreaks in intensive care Units [34].

Antibiotic profile were tested against all isolated species and it was clear that 100% resistance to ampicillin was recorded which is in agreement to the studies performed in Erbil/ Iraq and Egypt [35, 36]. However; this high level of resistance to ampicillin is not surprising due to constitutive expression of a chromosomally encoded B-lactamase (blaSHV-1) which confers resistance to ampicillin, amoxicillin, carbenicillin and ticarcillin [37].

The other drug such as amoxicillin-clavulanic acid also shows high resistance rate (96.29%), the same result was reported in Erbil, Najaf and Duhok / Iraq, [38, 39] and similar results were reported in Nigeria, Iran, Saudi Arabia [4042]. while lower resistance rate were recorded in a study done in Erbil-Kurdistan region-Iraq and Baghdad-Iraq [8, 43].

Regarding beta-lactam/beta-lactamase inhibitor combinations; the proportion of isolates showing resistance to amoxicillin/clavulanate (96.29%) was significantly higher than resistance to piperacillin/tazobactam (51.85%), the same result was recorded in Kingdom of Saudi Arabia [44]. The fact that piperacillin/tazobactam is less commonly used in this locality and in comparison to ampicillin which indicate over used of antibiotic causing selective pressure on bacteria for development of resistance.

The proportions of Klebsiella pneumoniae isolates showing resistance to non-beta-lactam agents such as trimethoprim (57.40%), ciprofloxacin (55.55%), gentamicin (53.70%), and amikacin (40.74%) were recorded, There is a bit difference with the result to what was recorded in a study done in Erbil-Sulaimani-Duhok/ Iraq by Khalid et al. [45], while imipenem and meropenem were the most susceptible antibiotics (63.0%) against Klebsiella pneumoniae isolates followed by Amikacin (59.26%), these results are in agreement with result of studies done in Erbil/Iraq and Iran [31, 41]. which stated that imipenem and meropenem were the most effective antibiotics, this result probably due to less frequent use of carbapenem to treat infection in compared to other antibiotics in this country. However, the emergence of resistance to carbapenem requires careful monitoring, as many of the producers are resistant to all antimicrobials posing a serious threat to hospital units, especially among immune compromise patients and among hospitalized patients. This finding was in agreement with data reported from other regional as well as global studies [31, 40, 46, 47] which may imply that increased use of carbapenems could potentially further select resistant strains.

The prevalence rate of ESBL was 51.85% among isolated Klebsiella pneumoniae by double disk diffusion method and VITEK 2 compact system, this result is in consistence with the study carried out in Erbil, Duhokin Iraq and in Iran [31, 39, 48], while higher rate was reported in Basrah-Iraq [49] and a lower rate was reported in a study that performed in Iran [50]. There are several studies from Turkey, Iran, Spain and Taiwan; recording prevalence rate of ESBL near to what was recorded in this study [41, 51, 52], this difference may be due to sample size type of clinical specimen. This variation in prevalence rate of ESBL may be due to differences in sample size.

The accurate detection of ESBL producing microorganisms is a major clinical problem in the laboratories, requiring not only phenotypic tests but also genotypic tests for all genes associated with β-lactamase production. The prevalence of β-lactamase producers and the distribution of ESBL genotypes are different from one year to another and even vary greatly in different geographical areas [53].

ESBL enzyme carries by several genes such as; SHV, TEM which were analyzed in this study, both genes (blaSHV and blaTEM) were detected by real-time PCR using specific primer sequences which yielded product sizes of 450 bp and 296 bp, respectively.

The result demonstrated that out of 28 ESBL positive strains 26 (92.85%) of them were positive for blaSHV while15 (53.57%) of them were positive for blaTEM. This means that 92.85% of ESBL producer Klebsiella pneumoniae were carried at least one of the both genes; similar result was reported in a study done in Erbil, Sulaimani and Duhok in Iraq by Khalid et al. [45]. This result was in agreement with several studies [36, 39, 52], whom they reported the prevalence of blaSHV gene in Klebsiella pneumoniae isolates near to the prevalence rate in this study but TEM gene were recorded a bit higher rate than this study.

Out of all ESBL positive isolates by phenotypic methods; 2 isolates showed negative result by genotyping; this may be due to presence of other ESBL genes such CTX-M, and OXA gene.

Resistance pattern among all isolated Klebsiella were analyzed and MDR strain were found in 59.25%; this indicate that not all samples carry MDR phenomenon. The remaining negative isolated may carry other genes such as AmpC, KPC, or other type carbapenemase enzyme but among all ESBL producers 75% were MDR, similar result were reported in a study in Erbil/ Iraq [2] and India [54]. This mostly due to the presence of multiple resistance gene on the same cassette of chromosomal, The plasmids that harbor ESBL genes also carry resistance genes for other antibiotic classes such as aminoglycosides, chloramphenicol, sulfonamides, trimethoprim, and tetracycline. Thus, Gram negative bacilli containing these plasmids mostly are multidrug-resistant bacteria [4]. Multi drug resistance K. pneumoniae strains have caused many disease problems worldwide with higher morbidity and mortality rates, posing a considerable threat to public health [38].

Conclusion

The prevalence and spread of ESBL-producing Klebsiella pneumoniae strains is worrisome and it is a frequent isolates among different clinical samples from different conditions, specifically from intensive care unit, both ESBL genes were isolated among Klebsiella Pneumoniae with prevalent of blaSHV over blaTEM gene.

Supporting information

S1 Data

(XLSX)

Acknowledgments

Particular thanks to Ministry of Health and General Health Directorate of Sulaimani with Department of Laboratory for granting to this work and special thanks to laboratory staff of microbiology department in Shar Teaching Hospital.

Data Availability

All relevant data are within the manuscript and its Supporting information files.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.Moland E. S., Kim S.-Y., Hong S. G. & Thomson K. S. Newer β-Lactamases: clinical and laboratory implications, Part I. Clinical Microbiology Newsletter. 2008: 30: 71–77. [Google Scholar]
  • 2.Gupta A., Ampofo K., Rubenstein D. & Saiman L. Extended spectrum β lactamase-producing Klebsiella pneumoniae infections’ review of the literature. Journal of erinatology. 2003. 23: 439. [DOI] [PubMed] [Google Scholar]
  • 3.Elnagar W., Habib E., Shokralla S., Barwa R., Abdel Galil K. & Abdulmageed E. Phenotypic and genotypic characterization of Extended Spectrum Beta-lactamases produced by Enterobacteriaceae. The Egyptian J. Med. Microbiol.2010. 19: 59–66. [Google Scholar]
  • 4.Rozwandwicz M., Brouwer M., Fischer J., Wagnaar J., Gonzalez–zorn B., Guerra B., et al. Plasmids carrying antimicrobial resistance genes in Enterobacteriaceae. J Antimicrob Chemother.2018.1:73(5):1121–1137. [DOI] [PubMed] [Google Scholar]
  • 5.Paterson D. L. & Bonomo R. A. Extended spectrum β-Lactamases: a Clinical Update. Clinical Microbiology Review. 2005. 18(4): 657–686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Pishtiwan A. H. & Khadija K. M. Prevalence of blaTEM, blaSHV, and blaCTX-M genes among ESBL-Producing Klebsiella pneumoniae and Escherichia coli isolated from Thalassemia Patients in Erbil, Iraq. Mediterranean journal of hematology and infectious diseases. 2019. 11(1):e2019041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Latipour M., Gholipour A. & Damavandi M. S. Prevalence of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae isolates in nosocomial and community-acquired urinary tract infections. Jundishapur journal of microbiology. 2016. 12:9(3):e31179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Mohammed I. and Abass E. Phenotypic detection of Extended Spectrum β-Lactamases (ESBL) among gram negative uropathogens reveals highly susceptibility to imipenem. Pak J Med Sci. 2019. 35(4): 1104–1109. doi: 10.12669/pjms.35.4.207 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Mawlood A. H., Omer S. A., Jalal S. T. & Haji S. H. Molecular detection of SHV-Type ESBL in E.coli and K. pneumoniae and their antimicrobial resistance profile. Zanco Journal of Medical Sciences. 2018.22, 262–272. [Google Scholar]
  • 10.Navon-Venzea S., Kondratyeva K. & Carattoli A. Klebsiella Pneumoniae: a major worldwide source and shuttle for antibiotic resistance. FEMS microbiology reviews. 2017. 41: 252–275. [DOI] [PubMed] [Google Scholar]
  • 11.Jean Ean S.-S. & Hsueh P.-R. High burden of antimicrobial resistance in Asia. International journal of antimicrobial agents. 2011. 37: 291–295. doi: 10.1016/j.ijantimicag.2011.01.009 [DOI] [PubMed] [Google Scholar]
  • 12.Tsai S.-S., Huang J.-C., Chean S.-T., Sun J.-H., Wang G C.-C., Lin S.-F., et al. Characteristics of Klebsiella pneumoniae bacteremia in community-acquired and nosocomial infections in diabetic patients. Chang Gung Med J.2010. 33: 532–9. [PubMed] [Google Scholar]
  • 13.Afroz H., Fakruddin M., Masud M. R. & Islam K. Incidence of and risk factors for hospital acquired infection in a tertiary care hospital of Dhaka, Bangladesh. Bangladesh Journal of Medical Science. 2017. 16:358–369. [Google Scholar]
  • 14.Luo Y., Wang Y., Ye E. L., & Yang J. Molecular epidemiology and virulence factors of pyogenic liver abscess causing Klebsiella pneumoniae in China. Clinical Microbiology and Infection.2014. 20:O818–O824. [DOI] [PubMed] [Google Scholar]
  • 15.Lee C.-R., Lee J. H., Park K. S., Kim Y. B., Jeong B. C. & Lee S. H. Global dissemination of Carbapenemase-producing Klebsiella pneumoniae: epidemiology, genetic context, treatment options, and detection methods. Frontiers in microbiology.2016. 7: 895. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Schwarz S., Silley P., Simjjee S., Woodford N., Van Duijkeren E., Johnson A. P., et al. Assessing the antimicrobial susceptibility of bacteria obtained from animals. Journal of antimicrobial chemotherapy. 2010. 65: 601–604. [DOI] [PubMed] [Google Scholar]
  • 17.Shariif N. M., Sreedevi B., Chaitanya R. & Sriltha C. Detection of extended spectrum beta-lactam (ESBL) resistance in Pseudomonas species of canine origin. The Pharma Innovation.2017. 6:89–96. [Google Scholar]
  • 18.Philippon A., Slama P., Deny P. & Labia R. A structure-based classification of class A β-lactamases, a broadly diverse family of enzymes. Clinical microbiology reviews.2016: 29:29–57. doi: 10.1128/CMR.00019-15 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Woodford N., Turton J. F. & Livermoor D. M. Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS microbiology reviews. 2011: 35: 736–755. doi: 10.1111/j.1574-6976.2011.00268.x [DOI] [PubMed] [Google Scholar]
  • 20.Malik T., Naim A. & Saeed A. Molecular Detection of TEM, SHV and CTX-M Genes Among Gram-negative Klebsiella Isolates. Current drug delivery 2018: 15:417–423. [DOI] [PubMed] [Google Scholar]
  • 21.CLSI 2018. Performance standards for antimicrobial susceptibility testing. Wayne, PA: Clinical and Laboratory Standards Institute.
  • 22.Hagia H., Watanabe N., Maki M., Murase T. & Otsuka F. Clinical utility of string test as a screening method for hypermucoviscosity-phenotype Klebsiella pneumoniae. Acute medicine & surgery. 2014: 1: 245–246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Shon A. S., Bajiwa R. P. & Russo T. A. Hypervirulent (hypermucoviscous) Klebsiella pneumoniae: a new and dangerous breed. Virulence. 2013: 4: 107–118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Anoar K. A., Ali F. A. & Omer S. A. Detection of Mettalo Beta-Lactamase enzyme in some Gram Negative bacterial isolates from burn patients in Sulaimani city / Iraq European Scientific Journal. 2014: 10: (3). [Google Scholar]
  • 25.Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. American Journal of Clinical Pathology. 1966.45(4):493–6. [PubMed] [Google Scholar]
  • 26.Garrec H., Drieux-Rouzet L., Golmard J.-L., Jariler V. & Robert J. Comparison of nine phenotypic methods for detection of extended-spectrum β-lactamase production by Enterobacteriaceae. Journal of clinical microbiology.2011: 49: 1048–1057. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Rangachari R. K., Kumar M. S. & Priyadarsini I. Detection of extended spectrum beta-lactamase producing gram negative bacilli in urinary isolates. Int J Biol Med Res. 2010: 1: 130–132. [Google Scholar]
  • 28.Batarseh HA., Soneah S., Mardeni R., Elmandi K. & Ashour N. A. Antibiotic resistant pattern of multi drug resistant and extended spectrum beta lactmase producing E.coli urinary isolates of Quine Rania Al- Abdullah hospital children. Zagazig University Medical Journal. 2015: 19:N.5. [Google Scholar]
  • 29.Ranjbar R., Fatahian K. Kelishadrokhi A. & Chehlgerdi M. Molecular characterization, serotypes and phenotypic and genotypic evaluation of antibiotic resistance of the Klebsiella pneumoniae strains isolated from different types of hospital-acquired infections. Infect Drug Resist. 2019: 12: 603–611. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Doosti A., Pourabbas M., Arshi A., Chehelgerdi M. & Kabiri H. TEM and SHV genes in Klebsiella pneumoniae isolated from cockroaches and their antimicrobial resistance pattern. Osong public health and research perspectives. 2015: 6: 3–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Ali F. A. & Ismael R. M. Dissemination of Klebsiella pneumonia and Klebsiella oxytoca Harboring bla TEM genes isolated from different clinical samples in Erbil City. Diyala Journal of Medicine. 2017: 12: 40–51. [Google Scholar]
  • 32.Catalan-Najera J. C., Garza-Ramos U. & Barrios-Camacho H. 2017. Hypervirulence and hypermucoviscosity: Two different but complementary Klebsiella spp. phenotypes? Virulence, 8: 1111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Remya P., Shanthi M. & SEKAR U. 2019. Characterization of virulence genes associated with pathogenicity in Klebsiella Pneumoniae. Indian journal of medical microbiology. 2019: 37:210–216. [DOI] [PubMed] [Google Scholar]
  • 34.Guo X., Cao Z., Dai Z., Li Y., He X., Hu X., et al. Antimicrobial Susceptibility and Molecular Epidemiology of Multidrug-Resistant Klebsiella pneumoniae in Central China. Jpn J Infect Dis. 2017: 70: 229–234. [DOI] [PubMed] [Google Scholar]
  • 35.Irajian G., Jazayeri M. A. & Beheshti A. Prevalence of extended-spectrum beta lactamase positive and multidrug resistance pattern of Escherichia coli and Klebsiella Pneumoniae isolates, Semnan, Iran. Iranian Journal of Pathology. 2009: 4 (3): 128–132. [Google Scholar]
  • 36.Tawgozy F. H. A. & Amin B. K. Molecular Analysis of Klebsiella Pneumoniae Isolated from UTI Patients in Erbil City. ZANCO Journal of Pure and Applied Sciences. 2018:30: 1–9. [Google Scholar]
  • 37.Haeggman S., Lofdahl S., Paauw A., Verhef J. & Brisse S. Diversity and evolution of the class A chromosomal beta-lactamase gene in Klebsiella Pneumoniae. Antimicrobial agents and chemotherapy. 2004: 48: 2400–2408. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Aljanaby A., Tuwaij N.SS. Al-khilkhali H.JB. Antimicrobial susceptibility patterns of Klebsiella pneumoniae isolated from older smokers and non-smokers of inpatients in intensive care unit infected with chronic pneumonia in AL-Najaf hospital, Iraq. / J. Pharm. Sci. & Res.2018: 10(5): 1093–1097. [Google Scholar]
  • 39.Qader M. K. Bacteriological and Molecular Study Characterization of Klebsiella pneumoniae Isolated from Different Clinical Specimens. UKH Journal of Science and Engineering. 2019: 3: 22–30. [Google Scholar]
  • 40.Iliyasu M., Uba A. & Agbo E. Phenotypic detection of multidrug resistant extended-spectrum beta-lactamase ESBL producing Escherichia coli from clinical samples. African Journal of Cellular Pathology.2018: 9: 25–32. [Google Scholar]
  • 41.Khosravi A. D., Hoveizavi H. & Mehdinejad M. Prevalence of Klebsiella Pneumoniae encoding genes for CTX-M-1, TEM-1 and SHV-1 extended-spectrum beta lactamases ESBL enzymes in clinical specimens. Jundishapur Journal of Microbiology. 2013: 6–15. [Google Scholar]
  • 42.AL-agamy M. H., Shibl A. M. & Tawfik A. F. Prevalence and molecular characterization of extended-spectrum β-lactamase-producing Klebsiella Pneumoniae in Riyadh, Saudi Arabia. Annals of Saudi medicine. 2009: 29: 253–257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Aziz R. A. R. & AL-JUBORI S. S. Genetic Elements Responsible for extreme drug resistance (XDR) in Klebsiella Pneumoniae var Pneumoniae isolated from clinical samples of Iraqi patients. World Journal of Pharmaceutical Research. 2016; (5): 2. [Google Scholar]
  • 44.Hassan M. I., Alkharsah K. R., Alzahrani A. J., Obeid O. E., Khamis A. H. & Diab A. Detection of extended spectrum beta-lactamases-producing isolates and effect of AmpC overlapping. The Journal of Infection in Developing Countries. 2013: 7: 618–629. doi: 10.3855/jidc.2919 [DOI] [PubMed] [Google Scholar]
  • 45.Khalid H. M., Yosif S. Y. & Jubarel J. M. 2013. Bacteriological and Molecular Characterization of Extended Spectrum Β-Lactamases in Clinical Isolates of Klebsiella Pneumoniae Isolated From Kurdistan Region, Iraq. Science Journal of University of Zakho. 2013: 1:158–163. [Google Scholar]
  • 46.Rudresh S. & Nagrathnamma T. Extended spectrum β-lactamase producing Enterobacteriaceae & antibiotic co-resistance. The Indian journal of medical research. 2011:133:116–119. [PMC free article] [PubMed] [Google Scholar]
  • 47.Hawser S. P., Bouchillon S. K., Lascols C., Hackel M., Hoban D. J., Badal R. E., et al. Susceptibility of Klebsiella Pneumoniae isolates from intra-abdominal infections and molecular characterization of ertapenem-resistant isolates. Antimicrobial agents and chemotherapy. 2011: 55: 3917–3921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Akbar D. A., Ali R. A. & Zahira K. Screening and prevalence of SHV/CTX-M/TEM Β-lactamase resistant gene in Klebsiella strains isolated bacteria from UTI in preschool age children in Jahroom Iran. 2016: 7:82–88. [Google Scholar]
  • 49.Alaghasan Z., Jasim U. & AL-mussawi A. A. Extended Spectrum β-lactamase ESBL-producing Klebsiella Pneumoniae isolated from Burn Wound Infections. Int. J. Curr. Microbiol. App. Sci. 2016. 5: 400–404. [Google Scholar]
  • 50.Kazemian H., Heidari H., Ghanavati R., Ghafourian S., Yazdani F., Sadeghifard N., et al. Phenotypic and Genotypic characterization of ESBLs, AmpC and Carbapenemase-Producing Klebsiella Pneumoniae and Escherichia coli Isolates. Med Princ Pract. 2019: 28: 547–551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Bahar I. H. Molecular characterization of TEM-and SHV-derived extended-spectrum beta-lactamases in hospital-based Enterobacteriaceae in Turkey. 2005: 58: 162–167. [PubMed] [Google Scholar]
  • 52.Diestra K., Coque T. M., Miro E., Oteo J., Nicolau C. J., Campos J., et al. Characterization and molecular epidemiology of ESBL in Escherichia coli and Klebsiella Pneumoniae in 11 Spanish hospitals (2004). Enfermedades infecciosas y microbiologia clinica. 2008: 26:404–410. [DOI] [PubMed] [Google Scholar]
  • 53.Pitout J. D. & Laupland K. B. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. The Lancet infectious diseases. 2008: 8: 159–166. [DOI] [PubMed] [Google Scholar]
  • 54.Bora A., Hazarika N. K., Shukla S. K., Prasad K. N., Sarma J. B. & Ahmed G. Prevalence of blaTEM, blaSHV and blaCTX-M genes in clinical isolates of Escherichia coli and Klebsiella Pneumoniae from Northeast India. Indian journal of Pathology and Microbiology. 2014: 57:249. [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Monica Cartelle Gestal

15 Nov 2021

PONE-D-21-32646Phenotypic and genotypic detection of extended spectrum beta lactamase enzyme in Klebsiella PneumoniaePLOS ONE

Dear Dr. Anoar,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================Please address the reviewers recommendations and prior to submission make sure that the manuscript has been well revised by several people. In its current form it has gramatical and spelling errors and the names of the bacteria contains spelling mistakes and it is not italics. Please, pay attention to the details. ==============================

Please submit your revised manuscript by Dec 30 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Monica Cartelle Gestal, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. 

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: N0 Line number Reviewer’s Comments/Suggestions

1 Abstract Most results of antibiotic not clarify clearly in abstract section

Keywords Need to arrange alphbetically

2 The manuscript contains many grammatical errors that must be corrected especialy the discussion and introduction section need too much correction

3 highlighted in Green Correct the word

4 highlighted in Red Delete word or character

5 Many Word not writed in fully form like” EBLS,ICU,U.S.A,MICs,OPD)and others, also the term EBLS sometimes writed “ESBLS” other palces writed “ESBLs” it must write in unique and scinetific style

6 Highlighted in Yellow Give a space

7 Results - İn this sectio the concentration of each antibiotiv must mentioned inside the (table 4).

- (P-value with 0.00001) this wrong value (correct the value).

8 Discussion The authors mentioned in this section this wrong reference lined with yellow” The other drug such as amoxicillin-clavulanic acid also shows high resistance rate (96.29%), the same result was reported in Erbil , Najaf and Duhok / Iraq (Gupta etal.(2003), (Aljanaby etal.(2018), (Qadir (2019). Respectively. So Gupta and his collegous study founded in U.S.A

9 References All the refernce not in one unique style; the year of publication sometime after the name of authors and sometimes after the title of article, sometiems after the year of publication come comma others semicolon

10 Others important notice - Many word wtrited wrongly like „standardise,Fifty four,30 µg must become

30µg (without any space),TEM and SHV writed with different format like balSHV,blasCTM

- Table 1,2 need to re-type in word format not in picture foramt

- Chi-sequare and correlation analysis test mentioned in statistical anlalysis section but actualy not calculate for the data (for comparision), the authors must delete these characters , also the authors must mentioned which version of M.soft excel they used

- Table 3, 4,5 ,6 and 7 must re-type again with word format adn without coluration .

- The manuscript not contanin conclusion and any Acknowledgement.

Reviewer #2: After reading the manuscript titled: I suggest the need for major revisions.

I believe that the presented research is very relevant and worth publishing, however the authors need to pay attention to a few issues detailed below. First of all, spelling inconsistencies, such as VITEK / Vitek, are noticeable. The authors do not pay attention to the correct spelling of the name of the microorganisms (no italics, no capital letters), the names of the authors cited are often written in lower case. Punctuation errors are also noticeable.

Introduction:

1) “Extended-spectrum beta-lactamase (ESBL)-producing bacteria is plasmid-mediated enzymes…” – should be corrected, bacteria aren’t enzymes!

2) “…evolutionary families based on their amino acid sequence TEM and sulphydryl variable SHV were the major types…” is this one sentence?

3) ” The fact that patients most likely to become infected with ESBL-producing Enterobacteriaceae are those…” – Enterobacteriaceae should be in italics

4) “It is estimated that Klebsiella species cause 8% of all hospital-acquired infections...” – Klebsiella should be in italics

5) “Antimicrobial resistance in Klebsiella Pneumoniae…” – pneumoniae should be lowercase

6) “Combinations of all types of bla genes were reported in this species, this may be due to either carriage of an antibiotic-resistant plasmid encoding an array of antibiotic resistance genes or due to acquisition of transposons containing different bla genes on the same plasmid” – bla should be in italics

7) “Many different techniques exist for confirming ESBL production , Phenotypic tests for ESBL detection” – this sentences should be separated by a period, not a comma. Do not put spaces in front of the punctuation marks

8) “(Schwarz etal.(2010)” – too much brackets

9) “(shariif etal.(2017).” – too much brackets, write surnames with capital letters

10) “Another confirming method involves at least an eight-fold reduction in the MICs of ceftazidime or cefotaxime in the presence of clavulanic acid, The isolates then reported as resistant to all penicillins, cephalosporins and aztreonam (muhamed & Abas 2019).” - Separate sentences with a period and not with a comma, and write surnames with a capital letter

11) “(philippon etal.(2011).” – surnames with a capital letter

Methods

1) shon etal.(2013). – surnames with a capital letter

2) biomeireux – company name should be write: bioMérieux

3) “Vitek® 2 biomeireux machine was used for the identification of all isolated Klebsiella according to the manufacturer’s recommendations” – which card was used?

4) tryptic soya broth - who is the medium’s producer?

5) Eppendoruf – correct to Eppendorf

6) “Antibiotic susceptibility pattern of Klebsiella pneumoniae isolates were performed according to the Kirby–Bauer disk diffusion method (Bauer etal.(1966) by using 15 commonly used antibiotic agents and all of the inoculated plates were aerobically incubated at 37°C for 18–24 hours, and the results were interpreted based on the instruction provided by the CLSI (2018 ).” - please mention here the antibiotics and their concentration

7) “disks” – correct to “discs” in each place

8) “Mueller-Hinton Agar plate” – no information about producer

9) VITEK or Vitek – please standardize

10) “Then let it to dissolve well and leave it for 15 minute at room temperature and mixed by vortexing, stock primer diluted 1:10 (10 μL of stock primer with 90 μL of DNA and RNA free distil water) to prepare working primer in concentration 10 pmol/μL (Ali& Ismael (2017).” - please correct the syntax so that it doesn't look like an instruction

Discussion

1) “this indicate that UTI is the most common infection in hospitals and Klebsiella is the second most common isolated bacteria” – Klebsiella should be in italics

2) “ICU samples . this indicates” – remove space before period and start sentence with a capital letter

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: manuscript-26-10-2021.docx

Attachment

Submitted filename: renamed_36ab1.docx

PLoS One. 2022 Sep 29;17(9):e0267221. doi: 10.1371/journal.pone.0267221.r002

Author response to Decision Letter 0


14 Dec 2021

1/ all Klebsiella pneumoniae were checked.

2/ tables written and putted in word format

3/ figure uploaded in APACE style

4/ Reference checked according to submission guide line

5/ all reviewer comment checked step by step

6/ 2 file uploaded one is manuscript ( re new one after correction ) , other revised one as follow : green word : corrected and newly added according to reviewer comment , red words : deleted word

7/ cover page checked according to file template of plos one \\

Attachment

Submitted filename: Respons to reviewer.docx

Decision Letter 1

Monica Cartelle Gestal

5 Apr 2022

Phenotypic and genotypic detection of extended spectrum beta lactamase enzyme in Klebsiella Pneumoniae

PONE-D-21-32646R1

Dear Dr. Anoar,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Monica Cartelle Gestal, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: JALEEL SAMANJE

Reviewer #2: No

Attachment

Submitted filename: Revised article 21-1-2022.docx

Acceptance letter

Monica Cartelle Gestal

7 Apr 2022

PONE-D-21-32646R1

Phenotypic and genotypic detection of extended spectrum beta lactamase enzyme in Klebsiella pneumoniae

Dear Dr. Anwar:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Monica Cartelle Gestal

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Data

    (XLSX)

    Attachment

    Submitted filename: manuscript-26-10-2021.docx

    Attachment

    Submitted filename: renamed_36ab1.docx

    Attachment

    Submitted filename: Respons to reviewer.docx

    Attachment

    Submitted filename: Revised article 21-1-2022.docx

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES